The company is developing bioreactor-grown mitochondria for transplant into the human body.
Disclosure: Longevity.Technology (a brand of First Longevity Ltd.) has been contracted by the company featured in this article to support its current funding round. Qualified investors can find out more through Longevity.Technology Investor Portal,
this week’s longevity summit dublin is in full swing, bringing together experts from around the world, promoting collaboration and exchange of knowledge in search of solutions to extend human health span. One of the speakers during today’s session was Stanford professor and surgeon, Dr. Vineet Mahajan, who is also chief medical advisor to the longevity biotech startup. matrix bio,
In his address to summit delegates in Dublin, Mahajan presented the company’s exciting preclinical technology: injecting bioreactor-grown mitochondria into the human body to regenerate organs, reverse age-related disease and support other longevity therapies. Designed to be implanted.
Matrix’s research suggests that many diseases of aging, including neurodegenerative, cardiovascular, retinal and infectious disorders, are caused by “unsustainable degeneration” of the short strand of DNA contained inside each mitochondrion. The company states that this degeneration leads to a decline in the energy produced, which leads to decreased cell efficiency, slower healing and accumulation of waste products.
‘Growing’ mitochondria in bioreactor
Mahajan describes how Matrix uses bioreactors – like those used for stem cells – to “grow” large quantities of healthy mitochondria, isolate them, coat them with a specially engineered protein coating coats it, and implants them into patients to be absorbed and used by the cells.
By growing additional mitochondria and implanting them into the body, Matrix aims to reverse the decline of cellular function and treat a wide range of aging-related diseases. The company suggests that its technology could particularly benefit the longevity field, providing the energy boost needed to support other potential therapies, such as epigenetic reprogramming.
Established two years ago, Matrix has assembled a world-class group of scientists to tackle the emerging field of mitochondrial transplantation. In addition to Mahajan, the company’s advisors include Dr. Michael Snyder, Chair of the Department of Genetics at Stanford University, and Dr. Thomas Rando, Director of the UCLA Broad Stem Cell Research Center.
Qualified investors can find out more about Matrix Bio through Longevity.Technology Investor Portal,
Investing in early-stage businesses involves risks including liquidity, lack of dividends, loss of investment and dilution, and should only be undertaken as part of a diversified portfolio. First Longevity is specifically targeted at sophisticated investors who understand these risks and make their own investment decisions. Investment opportunities not approved as financial promotion are not covered by the Financial Services Compensation Scheme (FSCS) and you may not have access to the Financial Ombudsman Service (FOS). If you have any doubts as to the steps to be taken or the content of the financial incentive received, you should consult your stockbroker, solicitor, accountant, bank manager or other professional advisor authorized under the Financial Services and Markets Act 2000, which is a non- Specializes in providing advice on bonds, shares and other securities including listed securities.
Past performance is not a reliable indicator of future performance. You should not rely on past performance as a guarantee of future investment performance. Tax relief depends on an individual’s circumstances and may change in future. Further, the availability of tax relief depends on the investments made by the company in maintaining its qualifying status.